National plaintiffs' law firm Berger Montague PCannounces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”) on behalf of investors who purchased MoonLake shares during the period ofMarch 10, 2024 through September 29, 2025 (the “Class Period”).
https://mma.prnewswire.com/media/232479/berger_montague.jpg
Investor Deadline: Investors who purchased MoonLakesecurities during the Class Period may, no later than December 15, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
MoonLake is a biopharmaceutical company headquartered in Zug, Switzerland, specializing in therapies for inflammatory diseases.
According to the complaint, the Company misled investors by aggressively touting its sole drug candidate,sonelokimab (SLK), as clinically superior to competing therapies due to its Nanobody structure. However, the lawsuit alleges thatthe Company failed to disclose that SLK targets the same molecules as FDA-approved BIMZELX and offered no demonstrated clinical advantage.
According to the complaint, onSeptember 28, 2025, the Company revealedPhase 3 clinical trial data showing SLK failed to match BIMZELX's efficacy. Analysts reportedly labeled the outcome as “disastrous,” and the Company's stockcollapsed by $55.75 per share – nearly 90% – in one trading day.
If you are a MoonLake investor and would like to learn more about this action, CLICK HEREor please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger MontagueBerger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigationsince its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:Andrew AbramowitzSenior CounselBerger Montague(215) 875-3015aabramowitz@bergermontague.com
Caitlin AdorniDirector of Portfolio & Institutional Client Monitoring ServicesBerger Montague(267) 764-4865cadorni@bergermontague.com
https://edge.prnewswire.com/c/img/favicon.png?sn=DC04597&sd=2025-10-22
View original content to download multimedia:https://www.prnewswire.com/news-releases/berger-montague-pc-investigating-claims-on-behalf-of-moonlake-immunotherapeutics-nasdaq-mltx-investors-after-class-action-filing-302591974.html
SOURCE Berger Montague
https://rt.newswire.ca/rt.gif?NewsItemId=DC04597&Transmission_Id=202510221806PR_NEWS_USPR_____DC04597&DateId=20251022